Physician profile
Daniel Y Wang
NPI 1346336195
$27,277.71
in general payments reported to CMS, 2019-2025
51 companies · $3,273 in 2025
The $3,273 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,011 · 2020: $3,892 · 2021: $4,284 · 2022: $3,685 · 2023: $3,624 · 2024: $3,508 · 2025: $3,273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,156.82 |
| Education | $249.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $6,208.64 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $2,777.85 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,332.50 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $1,734.11 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Pfizer INC. | $1,708.15 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,543.59 | 2019-2024 | Verquvo, Januvia, Belsomra |
| Amgen INC. | $1,537.77 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $1,210.19 | 2019-2025 | Freestyle Libre 3, Ensite |
| Janssen Pharmaceuticals, INC | $992.93 | 2019-2024 | Xarelto |
| Abbvie INC. | $833.92 | 2019-2023 | Vraylar |
| Sanofi-Aventis U.S. LLC | $801.96 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $702.36 | 2022-2025 | |
| Lilly USA, LLC | $693.67 | 2019-2025 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $615.70 | 2019-2024 | |
| Esperion Therapeutics, INC. | $438.89 | 2020-2025 | Nexletol |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.